<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161978</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00441-40</org_study_id>
    <nct_id>NCT02161978</nct_id>
  </id_info>
  <brief_title>Vascular Dysfunction and Antiangiogenic Therapy</brief_title>
  <acronym>DYVA-AAGG</acronym>
  <official_title>Micro and Macro Vascular Dysfunction Induced by Antiangiogenic Therapy: Identification of New Vascular Biomarkers (DYVA-AAGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      project is a pilot prospective, longitudinal, before-after, open label multicentric study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiangiogenic drugs and tyrosine kinase inhibitor (TKI) represent a new therapeutic issue in
      the treatment of several neoplasic tumors (colon, kidney, breast, lung, skin) and hemopathy.
      Antiangiogenic drugs acts through neutralization of the activity (e.g. bevacizumab) or the
      inhibition of post-receptor tyrosine kinase pathways (e.g. sunatinib, sorafenib), leading to
      a reduction and inhibition of the tumoral tissular neovascularization. Due to the ubiquitous
      role of and the systemic administration of the antiangiogenic drugs, almost all of them are
      responsible for several side effects, many involving the cardiovascular system (e.g. arterial
      hypertension, cardiomyopathies, proteinuria, bleedings,...) and leading to a reduction of the
      doses or withdrawal of the treatment. To date, the mechanism and the impact of these
      cardiovascular effects is not well understood involving structural (i.e. capillary
      rarefaction) and functional vascular dysfunction (i.e. vasomotor dysfunction, stiffening).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2012</start_date>
  <completion_date type="Actual">December 12, 2018</completion_date>
  <primary_completion_date type="Actual">December 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes induced by antiangiogenic drugs and tyrosine kinase inhibitor in the vascular ultrasound variables</measure>
    <time_frame>24 months</time_frame>
    <description>arterial stiffness, diameter and resistance will be performed using echotracking technologies.</description>
  </primary_outcome>
  <enrollment type="Actual">93</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Tumor Angiogenesis</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>CML (Chronic Myelogenous Leukemia)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated for a solid tumor (kidney, pancreas, intestinal, breast, lungs, skin)
        requiring a first or second line antiangiogenic therapy and Hemopathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women &gt; 18 years old treated for a solid tumor (kidney, pancreas, breast,
             lungs, skin) with line antiangiogneic therapy and hemopathy

          -  Antiangiogneic therapy can be: bevacizumab, anti- (e.g. sunitinib, sorafenib),
             proteinate kinases inhibitor (e.g.temsirolimus ) or everolimus or any new allowed
             therapy with expected antiangiogenic properties and tyrosine kinase inhibitor.

          -  Expected life span &gt; 6 months

          -  Clinical state allowing investigations

          -  A blood glucose and lipid tests within the last 3 months

        Exclusion Criteria:

          -  Informed consent not obtained

          -  Patients presenting a clinical state which does not allow for the performance of the
             vascular investigations (agitation, cutaneous wound, major asthenia, acute dyspnoea,
             cadiac arhythmia)

          -  Pregnant women

          -  Patients &gt; 18 yrs old protected by the french law

          -  Patients without national health insurance

          -  Patients included in another biomedical study (this criteria is relative to the other
             studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir HENNI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital, Angers, FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiangiogenic</keyword>
  <keyword>cancer</keyword>
  <keyword>vascular</keyword>
  <keyword>biomarker</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

